Medical Oncology

Apoptosis and Cell Growth Inhibition as Antitumor Effector Functions of Interferons
pp. 3-14(12)
Authors: Sangfelt O.; Strander H.

Prognostic Significance of Ki-67 Nuclear Proliferative Antigen, bcl-2 Protein, and p53 Expression in Follicular and Diffuse Large B-Cell Lymphoma
pp. 15-22(8)
Authors: Llanos M.; Alvarez-Argüelles H.; Alemán R.; Oramas J.; Díaz-Flores L.; Batista N.

Epirubicin, Cisplatin, and Prolonged or Brief Infusional 5-Fluorouracil in the Treatment of Carcinoma of Unknown Primary Site
pp. 23-32(10)
Authors: Karapetis C.S.; Yip D.; Virik K.; Strickland A.; Ryder K.; Cowling M.; Harper P.G.

Interference of Cytokeratin-20 and Mammaglobin-Reverse-Transcriptase Polymerase Chain Assays Designed for the Detection of Disseminated Cancer Cells
pp. 33-38(6)
Authors: Krüger W.H.; Jung R.; Detlefsen B.; Mumme S.; Badbaran A.; Brandner J.; Renges H.; Kröger N.; Zander A.R.

The Implication of Compromised Renal Function at Presentation in Myeloma: Similar Outcome in Patients Who Receive High-Dose Therapy: A Single-Center Study of 251 Previously Untreated Patients
pp. 39-50(12)
Authors: Sirohi B.; Powles R.; Mehta J.; Treleaven J.; Raje N.; Kulkarni S.; Rudin C.; Bhagwati N.; Horton C.; Saso R.; Singhal S.; Parikh P.

Serum Levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in Febrile Children with Cancer and Neutropenia
pp. 51-57(7)
Authors: Soker M.; Çolpan L.; Ece A.; Devecioglu C.; Haspolat K.

Biodistribution, Blood Half-Life, and Receptor Binding of a Somatostatin-Dextran Conjugate
pp. 59-64(6)
Authors: Behe M.; Du J.; Becker W.; Behr T.; Angerstein C.; Márquez M.; Hiltunen J.; Nilsson S.; Holmberg A.R.

Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support
pp. 65-77(13)
Authors: Gulbrandsen N.; Wisløff F.; Brinch L.; Carlson K.; Dahl I.M.; Gimsing P.; Hippe E.; Hjorth M.; Knudsen L.M.; Lamvik J.; Lenhoff S.; Løfvenberg E.; Nesthus I.; Lanng Nielsen J.; Turesson I.; Westin J.

Phase II Trial of Clarithromycin and Pamidronate Therapy in Myeloma
pp. 79-84(6)
Authors: Morris T.C.M.; Ranaghan L.; Morrison J.

Health-Related Quality of Life and Its Potential Prognostic Implications in Patients with Aggressive Lymphoma
pp. 85-94(10)
Authors: Jerkeman M.; Kaasa S.; Hjermstad M.; Kvaløy S.; Cavallin-Ståhl E.

Vinorelbine-Associated Myelopathy in a Patient Who Previously Received Paclitaxel
pp. 95-97(3)
Authors: Han J-Y.; Choi B.G.; Song D.H.; Ahn J.G.; Yoon J-S.; Lee K.S.